<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628860</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-13-709</org_study_id>
    <nct_id>NCT02628860</nct_id>
  </id_info>
  <brief_title>Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy</brief_title>
  <acronym>FCM</acronym>
  <official_title>Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study is to evaluate the safety and efficacy of Ferinject® in reducing
      perioperative transfusion in iron deficiency anemia patients anticipating
      pancreatoduodenectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives : Perioperative transfusion rate (including preop, intraop, postop≦7
      days).

      Secondary objectives : Postoperative complication, hospital stay, change of hematological
      parameters (Hb, ferritin, transferrin saturation (TSAT) change after Ferinject® injection),
      adverse effect with Ferinject® injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative transfusion rate</measure>
    <time_frame>from preoperative baseline within the first 7 days after surgery</time_frame>
    <description>To evaluate reducing transfusion rate during perioperative period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of complications after surgery as assessed by Clavien-Dindo classification of surgical complications</measure>
    <time_frame>up to 4-6 weeks after surgery</time_frame>
    <description>To investigate the association between the number of participants with complications and hospital length of stay(days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of hematology parameters</measure>
    <time_frame>up to 4-6 weeks after surgery</time_frame>
    <description>change of hematology parameters value of Hb in g/dL,
ferritin in ng/ml
transferrin saturation in % (TSAT) after Ferinject® administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>up to 4-6 weeks after surgery</time_frame>
    <description>assessment of adverse effect with Ferinject® administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ferinject to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight &lt;50 Kg .
Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® must be diluted only in sterile 0.9% sodium chloride.
Strength/Packaging: 10 mL vials containing 500 mg iron as iron per vial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject (Ferric Carboxymaltose)</intervention_name>
    <description>Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight &lt;50 Kg .
Study drug may be administered as IV drip infusion or IV undiluted bolus injection.</description>
    <arm_group_label>Ferinject</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥19 years old

          -  anticipating PD

          -  preoperative Hb of Female 7.0-11.9g/dl and Male 7.0-12.9g/dl

          -  signed written informed consent

        Exclusion Criteria:

          -  a concurrent medical condition(s) that would prevent compliance or participation or
             jeopardize the health of the patient

          -  hypersensitivity to any component of the formulation

          -  active severe infection/inflammation

          -  history of transfusion, erythropoietin, &gt;500 mg intravenous iron administration within
             4 weeks prior to screening.

          -  history of acquired iron overload.

          -  MCV &gt; 95µm3 or TSAT &gt; 35%

          -  patients with preoperative Hb&lt;7 g/dl

          -  pregnancy or lactation

          -  decreased renal function (defined as creatinine clearance &lt;50 L/min/1.73m2calculated
             by eGFR(MDRD))

          -  chronic liver disease or increase of liver enzymes (ALT, AST) &gt;5 times the upper limit
             of normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Jae Park, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Jae Park, M.D</last_name>
    <phone>+82-31-920-1640</phone>
    <email>spark@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sung Sik Han, M.D</last_name>
    <phone>+82-31-920-1641</phone>
    <email>sshan@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Jae Park, MD</last_name>
      <phone>82-31-920-1640</phone>
      <email>spark@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sung Sik Han, MD</last_name>
      <phone>82-31-920-1641</phone>
      <email>sshan@ncc.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jung Nam Joo, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sun Young Gong, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung Sik Han, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Woo Kim, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Woo Jin Lee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang Myeong Woo, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung Duk Lee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Park SJ, Kim SW, Jang JY, Lee KU, Park YH. Intraoperative transfusion: is it a real prognostic factor of periampullary cancer following pancreatoduodenectomy? World J Surg. 2002 Apr;26(4):487-92. Epub 2002 Feb 4.</citation>
    <PMID>11910485</PMID>
  </results_reference>
  <results_reference>
    <citation>Yeh JJ, Gonen M, Tomlinson JS, Idrees K, Brennan MF, Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. Br J Surg. 2007 Apr;94(4):466-72.</citation>
    <PMID>17330243</PMID>
  </results_reference>
  <results_reference>
    <citation>Peters JH, Carey LC. Historical review of pancreaticoduodenectomy. Am J Surg. 1991 Feb;161(2):219-25.</citation>
    <PMID>1990875</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaplan J, Sarnaik S, Gitlin J, Lusher J. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions. Blood. 1984 Jul;64(1):308-10.</citation>
    <PMID>6234037</PMID>
  </results_reference>
  <results_reference>
    <citation>Waymack JP, Gallon L, Barcelli U, Trocki O, Alexander JW. Effect of blood transfusions on immune function. III. Alterations in macrophage arachidonic acid metabolism. Arch Surg. 1987 Jan;122(1):56-60.</citation>
    <PMID>3492188</PMID>
  </results_reference>
  <results_reference>
    <citation>Innerhofer P, Tilz G, Fuchs D, Luz G, Hobisch-Hagen P, Schobersberger W, Nussbaumer W, Lochs A, Irschick E. Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus WBC-reduced blood transfusions in patients undergoing arthroplasty. II. Activation of T cells, macrophages, and cell-mediated lympholysis. Transfusion. 2000 Jul;40(7):821-7.</citation>
    <PMID>10924610</PMID>
  </results_reference>
  <results_reference>
    <citation>Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood. 1999 Mar 1;93(5):1770-7.</citation>
    <PMID>10029607</PMID>
  </results_reference>
  <results_reference>
    <citation>Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet. 1982 Sep 18;2(8299):662.</citation>
    <PMID>6125797</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990 Jul 1;66(1):56-61.</citation>
    <PMID>2354408</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Sang-Jae Park</investigator_full_name>
    <investigator_title>Head of Center for Liver Cancer, Chief of the Liver and Pancreatobiliary Cancer Branch</investigator_title>
  </responsible_party>
  <keyword>ferric carboxymaltose</keyword>
  <keyword>Ferinject®</keyword>
  <keyword>pancreatoduodenectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

